Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18700356 | 0.91 | KDM4E (0.47) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL3249905 | 0.86 | ALDH1A1 (0.55) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL29528196 | 0.85 | ALDH1A1 (0.50) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL16247191 | 0.85 | ALDH1A1 (0.50) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL14030546 | 0.85 | KDM4E (0.49) | KDM4ETDP1LMNAKMT2AMAPT | |
| Hydrogen Sulfide SCHEMBL21332270 | 0.84 | ALDH1A1 (0.49) | KDM4ETDP1LMNAKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL17583220 | 0.84 | KDM4E (0.48) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL14028790 | 0.83 | KDM4E (0.45) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL21332271 | 0.83 | MAPT (0.48) | KDM4ETDP1LMNAKMT2AMAPT | |
| SCHEMBL1137313 | 0.82 | ALDH1A1 (0.44) | KDM4ETDP1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3496763-B1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | GENENTECH, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-118436801-A | PROTAC antibody conjugates and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116249556-A | Antibody conjugation chemical inducer for degrading BRM and method thereof | 基因泰克公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2017064675-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2016044560-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016040825-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160074527-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20160074528-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160074528-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | KDM4E 3738/4885TDP1 4175/4885LMNA 1480/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | KDM4E 2636/4885TDP1 3630/4885LMNA 2374/4885 |
| US-20160074527-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | CD79B, PA2G4, SBDS | KDM4E 2944/4885TDP1 4567/4885LMNA 4650/4885 |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | ADRM1, SSB, FCER2 | KDM4E 2623/4885TDP1 2463/4885LMNA 1228/4885 |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GABRA5, BCR, GABRA4 | KDM4E 1674/4885TDP1 3990/4885LMNA 4600/4885 |
| US-20160074528-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | PDIA5, PDIA4, PDIA6 | KDM4E 3295/4885TDP1 4120/4885LMNA 4482/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | KDM4E 3411/4885TDP1 4712/4885LMNA 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.